tradingkey.logo

STAAR Surgical Co

STAA
27.400USD
-0.010-0.04%
Close 11/11, 16:00ETQuotes delayed by 15 min
1.35BMarket Cap
LossP/E TTM

STAAR Surgical Co

27.400
-0.010-0.04%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of STAAR Surgical Co

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

STAAR Surgical Co's Score

Industry at a Glance

Industry Ranking
73 / 209
Overall Ranking
168 / 4608
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 9 analysts
Hold
Current Rating
24.625
Target Price
-10.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

STAAR Surgical Co Highlights

StrengthsRisks
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -14.03, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.83M shares, decreasing 23.09% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 15.52K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.61.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 7.29, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 94.73M, representing a year-over-year increase of 6.93%, while its net profit experienced a year-over-year increase of 10.98%.

Score

Industry at a Glance

Previous score
7.29
Change
0

Financials

7.29

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.37

Operational Efficiency

7.22

Growth Potential

7.31

Shareholder Returns

7.25

STAAR Surgical Co's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 7.22, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -14.03, which is -1280.06% below the recent high of 165.61 and -332.87% above the recent low of -60.75.

Score

Industry at a Glance

Previous score
7.22
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 73/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for STAAR Surgical Co is 28.00, with a high of 28.00 and a low of 16.00.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts
Hold
Current Rating
24.625
Target Price
-10.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
STAAR Surgical Co
STAA
9
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Dexcom Inc
DXCM
30
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 8.15, which is higher than the Healthcare Equipment & Supplies industry's average of 7.18. Sideways: Currently, the stock price is trading between the resistance level at 28.95 and the support level at 24.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.02
Change
0.13

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.300
Neutral
RSI(14)
56.479
Neutral
STOCH(KDJ)(9,3,3)
84.919
Buy
ATR(14)
1.279
Low Volatility
CCI(14)
90.077
Neutral
Williams %R
15.449
Overbought
TRIX(12,20)
-0.046
Sell
StochRSI(14)
99.458
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
26.648
Buy
MA10
26.277
Buy
MA20
26.147
Buy
MA50
26.754
Buy
MA100
24.191
Buy
MA200
21.217
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 100.45%, representing a quarter-over-quarter decrease of 8.33%. The largest institutional shareholder is The Vanguard, holding a total of 4.26M shares, representing 8.56% of shares outstanding, with 27.82% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Broadwood Capital, Inc.
13.52M
--
BlackRock Institutional Trust Company, N.A.
6.72M
-4.26%
The Vanguard Group, Inc.
Star Investors
4.38M
-18.96%
Armistice Capital LLC
2.81M
-6.27%
Yunqi Capital Limited
2.50M
+3.68%
State Street Investment Management (US)
2.00M
+0.40%
Geode Capital Management, L.L.C.
1.19M
+0.28%
BofA Global Research (US)
1.15M
+20.30%
Morgan Stanley & Co. LLC
873.98K
+81.82%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 4.49, which is lower than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.49
Change
0
Beta vs S&P 500 index
1.00
VaR
+5.53%
240-Day Maximum Drawdown
+48.14%
240-Day Volatility
+80.41%

Return

Best Daily Return
60 days
+8.27%
120 days
+46.13%
5 years
+46.13%
Worst Daily Return
60 days
-6.71%
120 days
-7.00%
5 years
-24.68%
Sharpe Ratio
60 days
-0.19
120 days
+1.27
5 years
-0.15

Risk Assessment

Maximum Drawdown
240 days
+48.14%
3 years
+80.98%
5 years
+90.72%
Return-to-Drawdown Ratio
240 days
-0.08
3 years
-0.17
5 years
-0.17
Skewness
240 days
+3.70
3 years
+2.08
5 years
+1.32

Volatility

Realised Volatility
240 days
+80.41%
5 years
+64.84%
Standardised True Range
240 days
+3.79%
5 years
+11.71%
Downside Risk-Adjusted Return
120 days
+356.02%
240 days
+356.02%
Maximum Daily Upside Volatility
60 days
+28.40%
Maximum Daily Downside Volatility
60 days
+30.41%

Liquidity

Average Turnover Rate
60 days
+3.24%
120 days
+2.56%
5 years
--
Turnover Deviation
20 days
+261.25%
60 days
+77.73%
120 days
+40.56%

Peer Comparison

Healthcare Equipment & Supplies
STAAR Surgical Co
STAAR Surgical Co
STAA
7.18 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Boston Scientific Corp
Boston Scientific Corp
BSX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.55 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI